Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Given a $7.00 Price Target at Maxim Group

Maxim Group set a $7.00 price target on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in a research note published on Wednesday, August 9th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Achillion Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, July 11th. BidaskClub upgraded shares of Achillion Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, July 6th. Robert W. Baird lifted their target price on shares of Achillion Pharmaceuticals from $5.00 to $10.00 and gave the company an outperform rating in a research note on Monday, April 24th. Leerink Swann upgraded shares of Achillion Pharmaceuticals from a market perform rating to an outperform rating and lifted their target price for the company from $4.00 to $6.00 in a research note on Thursday, May 18th. Finally, Jefferies Group LLC reiterated a hold rating on shares of Achillion Pharmaceuticals in a research note on Wednesday, April 26th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $8.25.

Achillion Pharmaceuticals (NASDAQ:ACHN) traded down 4.30% during trading on Wednesday, hitting $4.67. The company had a trading volume of 1,489,155 shares. The firm’s 50 day moving average is $4.45 and its 200-day moving average is $4.16. The stock’s market capitalization is $638.67 million. Achillion Pharmaceuticals has a 52-week low of $3.15 and a 52-week high of $9.49.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). During the same quarter in the previous year, the company earned ($0.14) earnings per share. On average, equities analysts forecast that Achillion Pharmaceuticals will post ($0.63) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Given a $7.00 Price Target at Maxim Group” was originally posted by BNB Daily and is owned by of BNB Daily. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/achillion-pharmaceuticals-inc-nasdaqachn-pt-set-at-7-00-by-maxim-group-updated.html.

Large investors have recently made changes to their positions in the stock. Cambridge Investment Research Advisors Inc. raised its stake in shares of Achillion Pharmaceuticals by 3.6% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 800 shares during the period. Deschutes Portfolio Strategy LLC raised its stake in shares of Achillion Pharmaceuticals by 13.4% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 3,000 shares during the period. SG Americas Securities LLC raised its stake in shares of Achillion Pharmaceuticals by 18.6% in the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 4,144 shares during the period. Teza Capital Management LLC acquired a new stake in shares of Achillion Pharmaceuticals during the first quarter valued at about $131,000. Finally, TradeLink Capital LLC acquired a new stake in shares of Achillion Pharmaceuticals during the second quarter valued at about $132,000. 70.70% of the stock is currently owned by hedge funds and other institutional investors.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply